656 related articles for article (PubMed ID: 23291583)
1. Recurrent ALK-negative anaplastic large T-cell lymphoma presenting as necrotizing vasculitis.
Nambudiri VE; Aboutalebi A; Granter SR; Saavedra A
Am J Dermatopathol; 2013 Jun; 35(4):512-6. PubMed ID: 23291583
[TBL] [Abstract][Full Text] [Related]
2. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules.
Bird JE; Leitenberger JJ; Solomon A; Blauvelt A; Hopkins S
Dermatol Online J; 2012 May; 18(5):5. PubMed ID: 22630575
[TBL] [Abstract][Full Text] [Related]
3. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
[TBL] [Abstract][Full Text] [Related]
5. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
[TBL] [Abstract][Full Text] [Related]
6. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative.
Kadin ME; Pinkus JL; Pinkus GS; Duran IH; Fuller CE; Onciu M; Kawaguchi H; Morris SW
Am J Surg Pathol; 2008 Sep; 32(9):1421-6. PubMed ID: 18670345
[TBL] [Abstract][Full Text] [Related]
7. Primary Cutaneous Sarcomatoid Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma With Linear Distributional Lesions.
Chen H; Xiong JS; Sheng N; Zong WK; Wang YH; Li M; Sun JF
Am J Dermatopathol; 2017 Nov; 39(11):863-866. PubMed ID: 29053547
[TBL] [Abstract][Full Text] [Related]
8. ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course.
Wehkamp U; Oschlies I; Nagel I; Brasch J; Kneba M; Günther A; Klapper W; Weichenthal M
J Cutan Pathol; 2015 Nov; 42(11):870-7. PubMed ID: 26053561
[TBL] [Abstract][Full Text] [Related]
9. ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient.
Pulitzer M; Ogunrinade O; Lin O; Steinherz P
J Cutan Pathol; 2015 Mar; 42(3):182-187. PubMed ID: 25404214
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
12. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
Shi Y; Chen G; Zhou XG; Gong LP; Yu R; Zheng YY; Xie JL; Jin Y
Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):235-9. PubMed ID: 20654121
[TBL] [Abstract][Full Text] [Related]
15. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.
ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R; Falini B; Chott A; Meijer CJ
J Clin Pathol; 2000 Jun; 53(6):445-50. PubMed ID: 10911802
[TBL] [Abstract][Full Text] [Related]
16. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
[No Abstract] [Full Text] [Related]
17. [ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin].
Arai H; Furuichi S; Nakamura Y; Nakamura Y; Ichikawa M; Mitani K
Rinsho Ketsueki; 2016 May; 57(5):634-7. PubMed ID: 27263791
[TBL] [Abstract][Full Text] [Related]
18. Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity.
Metcalf RA; Bashey S; Wysong A; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2013 Apr; 37(4):617-23. PubMed ID: 23480896
[TBL] [Abstract][Full Text] [Related]
19. A Case of ALK+ Anaplastic Large-Cell Lymphoma With Aberrant Myeloperoxidase Expression and Initial Cutaneous Presentation.
Gru AA; Voorhess PJ
Am J Dermatopathol; 2018 Jul; 40(7):519-522. PubMed ID: 29905579
[TBL] [Abstract][Full Text] [Related]
20. ALK-negative systemic intravascular anaplastic large cell lymphoma presenting in the skin.
Rieger KE; Polidore T; Warnke R; Kim J
J Cutan Pathol; 2011 Feb; 38(2):216-20. PubMed ID: 20236372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
